Background. The relationship between Epstein-Barr virus (EBV) and breast cancer (BC) is controversial. Interleukin-10 (IL-10) and interferon-c (IFN-c) are believed to play a critical role in the host's responses to EBV infection, and their genetic variations may modify the association of EBV with BC risk.
Breast cancer is the most common cancer in women worldwide [1] . Viral infection is suspected to be involved in breast cancer carcinogenesis, and Epstein-Barr virus (EBV) has received considerable interest as the candidate virus [2, 3] . The majority of previous studies have focused on searching for EBV genome or its expression in breast cancer tissues, and EBV presence varied notably in different studies (from 0% to 50% of tumors) [3, 4] . Several serological studies have evaluated the association between EBV immunoglobulin G (IgG) antibodies and breast cancer risk, but the results have also been conflicting [5] [6] [7] [8] [9] . Given that the presence of immunoglobulin A (IgA) to EBV antigens suggests the reactivation of latent EBV or repeated viral infection of EBV in epithelia [10] , we recently found that IgA antibodies against EBV viral capsid antigen (VCA) and nuclear antigen-1 (EBNA-1), which are effective biomarkers in the screening and diagnosis of nasopharyngeal carcinoma (NPC), were positively associated with breast cancer risk in Guangzhou, China, a high-incidence area of NPC [11] . However, we also found that this association was not absolute. Moreover, EBV is a ubiquitous herpesvirus and infects .90% of adults worldwide [12] , but only a small proportion of infected individuals develop EBV-related tumors and the incidence of EBV-related tumors has great geographical disparities among different regions [13] . Hence, there must be vast differences in individual susceptibility to EBV-related tumors.
EBV infection (latent or lytic infection) results in both humoral and cellular immune responses. As immune mediators, cytokines are believed to play a critical role in the responses against EBV infection [14] . Interferon-c (IFN-c) is a T helper (Th) type 1 cytokine and is secreted mainly by activated T cells, natural killer (NK) cells, and NKT cells [15] . It plays a major role in defense against viruses and intracellular pathogens and induces immune and inflammatory responses by activating macrophages, NK cells, and T cells [15] . IFN-c has also been reported to inhibit EBV-transformed B-cell outgrowth in vitro [16] . In contrast, interleukin-10 (IL-10), a Th 2 cytokine produced primarily by activated T cells, monocytes, and B cells, has multiple effects on the regulation of immune and inflammatory responses [17] . The major effects of IL-10 are that it limits cellular immune responses by inhibiting the activation of T cells, macrophages, and monocytes, and it is generally thought to be immunosuppressive [17] . These biological activities of IL-10 may facilitate EBV infection and persistence. It is intriguing that EBV encodes BCRF1 protein, which shares properties similar to IL-10 [18] , and BZLF1 protein, which inhibits the IFN-c signaling pathway [19] . Therefore, we focused on the IL-10 and IFN-c genes to evaluate the effect modification in the association of breast cancer risk with EBV IgA levels.
Three single-nucleotide polymorphisms (SNPs) in the IL-10 promoter region, including rs1800896 (-1082A/G), rs1800871 (-819C/T), and rs1800872 (-592C/A), which are in strong linkage disequilibrium (LD), have been reported to influence the expression of IL-10 [20, 21] and to be associated with susceptibility and outcome of EBV infection [22, 23] . It has also been reported that SNP rs1800871 of IL-10 was associated with EBV IgG titers [24] . For IFN-c, rs2069705 (-1615 C/T) has been reported to be associated with breast cancer risk [25] . This SNP was also found to be associated with susceptibility to systemic lupus erythematosus (SLE, a disease highly related to IFN-c level) [26] , indicating that it is associated with IFN-c expression.
In the present study, we enlarged the sample size to reevaluate the association between EBV IgA antibodies and breast cancer risk, and we further investigated whether this association was modified by IL-10 (rs1800871) and IFN-c (rs2069705) polymorphisms in a case-control study in Guangzhou, China.
SUBJECTS, MATERIALS, AND METHODS

Subjects
Female patients newly histologically diagnosed with breast cancer were consecutively recruited to this study between October 2008 and February 2010 from the First and the Second Affiliated Hospitals of Sun Yat-sen University in Guangzhou, China. Women with metastasized breast cancer or previous history of other cancers were excluded. A total of 354 eligible breast cancer cases completed in-person interviews and donated blood samples with response proportions of 75%-85% depending on the hospitals. Cancer-free controls, frequency-matched to the cases for age (65 years) and residential area, were recruited from women who attended a health checkup in the same hospitals during the same period. Of the eligible controls, 504 (91.8%) completed in-person interviews and donated blood samples. The cases and controls were interviewed face-to-face by trained interviewers using the same questionnaire. Informed consent was obtained from all study participants. The Ethical Committee of the School of Public Health at Sun Yat-sen University approved the study.
The following information was obtained from the interview: menstrual and reproductive history, lifestyle, family history of cancer, height and weight, and demographic factors. Blood samples were collected immediately after admission to the hospital for patients or after the interview for controls. Serum samples were stored at 280°C.
Serological Tests
IgA antibodies against EBV VCA-p18 and EBNA-1 were examined using commercial enzyme-linked immunosorbent assay kits (Zhongshan Bio-Tech), which is a routine method for NPC screening and diagnosis in NPC high-risk areas in China. The tests were performed according to the manufacturer's instructions. The laboratory technicians were blinded to the status of case and control. A reference sample provided with the kit was placed in each 96-well plate to standardize the optical density (OD) value between test plates. Seropositivity was defined as OD . 0.30 for VCA IgA and OD . 0.55 for EBNA-1 IgA.
Genotyping
Genomic DNA was extracted from peripheral blood cells of the participants using the TIANamp Genomic DNA Kit (TianGen Biotech). DNA from 5 cases and 4 controls (in the old set subjects) was not available or failed to be extracted. Genotyping was performed using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry platform (Sequenom), according to the manufacturer's instructions. This method is high-throughput and relatively economic; the results feature high reliability and reproducibility. The details of the primers are described in Supplementary Table 1. Duplicate samples (5% of the total) were included for evaluation of genotyping quality, and the concordance rates were 100%. Genotyping was successfully performed among 347 (99.4%) cases and 496 (99.2%) controls for IL-10 rs1800871, and among 346 (99.1%) cases and 490 (98.0%) controls for IFN-c rs2069705. No deviation from the Hardy-Weinberg equilibrium was observed (P 5 .776 and 0.804 for rs1800871 and rs2069705, respectively, in the control group).
Statistical Analysis
The differences in demographic characteristics and common risk factors for breast cancer between the cases and controls were tested using the v 2 test (for categorical variables) or Student equilibrium for IL-10 rs1800871 and IFN-c rs2069705 was evaluated by a goodness-of-fit v 2 test to compare the observed genotype frequencies with the expected ones among the controls. Levels of IgA to VCA or EBNA-1 were presented as seropositivity and OD value (as a continuous variable). We further combined the seropositivities of VCA IgA and EBNA-1 IgA as a whole to evaluate the associations of EBV IgA levels with the risk of breast cancer. Combined EBV IgA was considered positive if either VCA or EBNA-1 IgA was positive; combined EBV IgA was considered negative if both VCA and EBNA-1 IgA were negative. The associations between IgA levels and genotypes were evaluated using the v 2 test or Wilcoxon rank-sum test in healthy controls. The variant homozygotes and heterozygotes were combined because of their small sample sizes in the homozygotes assuming a dominant model for IL-10 rs1800871 and IFN-c rs2069705.
Associations between IgA levels, genotypes, and breast cancer risk were explored using multivariate logistic regression, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. The following variables were included in the multivariable analysis for adjustment: age, education (#9 vs 9.1-12, .12), marital status (never married vs married or living as married, separated, or widowed), body mass index (BMI; ,24 vs 24.0-27.9, $28.0), age at menarche (#12.0 vs 12.1-13.9, $14), menopausal status (premenopausal vs postmenopausal), parity (0 vs 1, $2), breastfeeding (never vs ever), and family history of breast cancer (absent vs present). The interaction between IgA levels and genotypes on breast cancer risk were evaluated by a multiplicative model and an additive model. We tested for multiplicative interaction by including the product term in multivariate logistic regression. Additive interaction was assessed by bootstrapping (5000 resamples).
Statistical significance was set at P , .05. Statistical analyses were performed using statistical software SPSS, version 13.0 (SPSS, an IBM Company). The bootstrapping was implemented by R software, version 2.12.1 (R Development Core Team, 2010; available at http://www.R-project.org). Power calculations were performed with the Gauderman and Morrison QUANTO program (version 1.2.4, 2009; available at http:// hydra.usc.edu/gxe) [27] . Table 1 shows that distributions of age, marital status, BMI, age at menarche, age at menopause, breastfeeding, hormone therapy, and family histories of breast cancer and nasopharyngeal carcinoma did not significantly differ between the cases and controls. However, breast cancer cases were more likely to be less educated, premenopausal, and nulliparous (Table 1) .
RESULTS
Results for EBV IgA antibodies were similar to those in our previous report [11] . VCA IgA levels were significantly associated with an elevated risk of breast cancer, and the ORs for seropositivity and unit increase in OD value of VCA IgA were 1.76 (95% CI, 1.17-2.63) and 2.11 (95% CI, 1.24-3.61), respectively, in a multivariate model (Table 2 ). For EBNA-1 IgA, unit increase in OD value, but not seropositivity, was significantly associated with breast cancer risk, and the OR was 2.33 (95% CI, 1.11-4.89) ( Table 2 ). The results for the combination of VCA IgA and EBNA-1 IgA were similar to those for VCA IgA alone (Table 2 ). We performed separate analyses for the subjects of the old set and the new set. Similar results were generated by the 2 sets, although the increased breast cancer risk of VCA IgA was not significant in the new set, due probably to the small sample size (Supplementary Table 2 ).
Frequencies of TT and TC/CC of IL-10 rs1800871 were 0.51 and 0.49 in the cases, and 0.46 and 0.54 in the controls, respectively. In the multivariate logistic regression analysis, the TC/CC genotype of rs1800871 was significantly associated with a reduced breast cancer risk compared with the TT genotype, and the OR was 0.74 (95% CI, .55-1.00) ( Table 2 ). Genotypes of IFN-c rs2069705 were equally distributed in the cases and controls and consequently not significantly associated with breast cancer risk ( Table 2) .
We further analyzed the joint effects between EBV IgA antibodies and polymorphisms in IL-10 or IFN-c on the risk of breast cancer. According to the EBV IgA levels (binary) and genotypes (binary) of IL-10 rs1800871 or IFN-c rs2069705, subjects were divided into 4 groups. For IL-10 rs1800871, women with VCA IgA seronegativity and TT genotype, VCA IgA seropositivity and TC/CC genotypes, and VCA IgA seropositivity and TT genotype had increasing risks of breast cancer, compared with those with VCA IgA seronegativity and TC/CC genotypes, and the adjusted ORs were 1.28 (95% CI, .92-1.78), 1.61 (95% CI, .89-2.89), and 2.63 (95% CI, 1.49-4.64), respectively (Table 3) . Although the interaction in multiplicative or additive models was not observed, the linear trend was significant (Table 3) . Results for EBNA-1 IgA and combined EBV IgA were similar to those for VCA IgA alone (Table 3) .
For IFN-c rs2069705, compared with those with VCA IgA seronegativity and CC genotype, the adjusted ORs for women with VCA IgA seronegativity and CT/TT genotypes, VCA IgA seropositivity and CC genotype, and VCA IgA seropositivity and CT/TT genotypes were 1.05 (95% CI, .76-1.45), 1.74 (95% CI, 1.00-3.03), and 2.03 (95% CI, 1.12-3.71) ( Table 3 ). There was no interaction between VCA IgA and genotype of IFN-c rs2069705 on the risk of breast cancer, but the linear trend was also significant (Table 3) . However, a marked interaction between EBNA-1 IgA and IFN-c genotypes was observed (P values for multiplicative and additive interactions were .003 and .005, respectively). The risk of breast cancer was greatest in women with EBNA-1 IgA seropositivity and CC genotype of IFN-c rs2069705 versus those with EBNA-1 IgA seronegativity and the CC genotype (OR, 5.14 [95% CI, 1.76-14.98]) (Table 3 ). There was no significant increased risk of breast cancer in women with the CT/TT genotypes regardless of EBNA-1 IgA status. A pattern similar to that of EBNA-1 IgA was observed for combined EBV IgA, but the interaction was not significant (Table 3 ).
In addition, there was no significant correlation between seropositivity or OD value of EBV IgA antibodies and genotypes of IL-10 rs1800871 and IFN-c rs2069705 (Supplementary Table 3 ). No joint effect of IL-10 rs1800871 and IFN-c rs2069705 on breast cancer risk was observed (Supplementary Table 4 ).
DISCUSSION
In this case-control study conducted in a high-incidence area of NPC with an enlarged sample size, we confirmed our previous finding of a positive association between EBV IgA antibodies and breast cancer risk [11] . We further explored whether this association would be modified by polymorphisms of IL-10 rs1800871 and IFN-c rs2069705.
Numerous studies have examined the association between IL-10 polymorphisms and the risk of cancers, including breast cancer [28] . The SNPs of rs1800871, together with rs1800896 and rs1800872, were the most widely examined SNPs in those studies [28] . These 3 SNPs were in strong LD, especially complete LD between rs1800871 and rs1800872, and the rs1800871 T allele (in exact LD with the rs1800872 A allele) is strongly associated with the presence of the ATA haplotype formed by SNPs of rs1800896, rs1800871, and rs1800872 in whites and Asians [21, 29] . Our findings, an association of the T allele in rs1800871 (equivalent to the A allele in rs1800872) with an elevated breast cancer risk, were in line or partially in line with the results from studies of Giordani et al [30] among Italians, Langsenlehner et al [31] among Austrians, and Kong et al [32] among Chinese. However, some studies showed no relationship of genotypes or haplotypes of rs1800896, rs1800871, and rs1800872 with breast cancer risk [33] [34] [35] [36] or an opposite association [37] to ours. The reasons for the conflicting results may be complicated. Previous reports correlating the IL-10 genotype and IL-10 levels have been contradictory. Helminen et al [23] suggested that the ATA haplotype was associated with increased IL-10 levels, whereas Turner et al [21] reported that IL-10 levels were lower in subjects with the rs1800896 A allele or the ATA haplotype. In addition, IL-10 may act as a doubleedged sword on breast cancer risk [37, 38] . On the one hand, the effects of IL-10 are to limit cellular immune responses by inhibiting the activation of T cells, macrophages, and monocytes, and are thought to facilitate development of cancer by supporting tumor escape from the immune response [17] . On the other hand, antiangiogenic effects of IL-10 are supposed to prevent or reduce tumor growth and metastasizing [37, 38] . In the present study, we also observed neither a relationship between the IL-10 genotype and levels of EBV IgA antibodies nor an interaction between them on breast cancer risk. Previous studies have yielded inconsistent data about the associations of IL-10 with EBV infection. IL-10 is usually considered to be an antiinflammatory cytokine that inhibits NK and T-cell activity and thus controls the strong inflammatory response after EBV primary infection [39] . However, Stewart et al [40] and Kurilla et al [41] showed that IL-10 enhanced the activation of NK cell immune response against EBV and decreased viral replication. Due to the multiple biological functions of IL-10 and confusion about the relationship between IL-10 genotypes and its expression, we cannot explain how the genotypes of IL-10 rs1800871 affect susceptibility to breast cancer or EBV infection. The association and interaction between EBV infection, IL-10 genotypes and its expression levels on breast cancer risk remain to be studied. We found that IFN-c rs2069705 was not directly associated with breast cancer risk but significantly modified the association of EBV infection with the risk of breast cancer. IFN-c was thought to protect the host against EBV infection via direct antiviral effects as well as modulation of the immune response. IFN-c also inhibits the growth of many cell lines that originated from tumors, including breast cancer [42] , and a high level of IFN-c expression shows antitumor activity [43] . The SNP of rs2069705 is located in the IFN-c gene promoter region. Kim et al [26] recently found that the T allele in this SNP was exclusively associated with a high risk of SLE, a disease related to high expression levels of IFN-c [44] , after they scrutinized all potential functional SNPs in the IFN-c gene in a Korean population. This suggested that the T and C alleles in rs2069705 are associated with high and low expression levels of IFN-c, respectively. Moreover, although the effects of rs2069705 on IFN-c expression have not been confirmed by in vitro study, an SNP (rs2430561) in moderate LD with rs2069705 in intron 1 has been demonstrated to affect the IFN-c expression level, as the minor A allele (linked to the T allele in rs2069705) had higher affinity to nuclear transcription factor NF-jB in an electrophoretic mobility shift assay [45] and showed a higher enhancer activity in an expression report assay than did the T allele [26, 46] . This evidence would help in interpreting the interaction between EBV infection and IFN-c rs2069705 shown in the present study. A low level of IFN-c in a host with the CC genotype in rs2069705 may, on the one hand, attenuate its antitumorigenic effect. However, it may also decrease the inhibition of carcinogenic properties of EBV reactivation, resulting in women with seropositivity of EBNA-1 IgA and the CC genotype having a significantly increased breast cancer risk. In addition, a few previous studies examined the association of polymorphisms in the IFN-c gene, mainly rs2069705 (-1615 C/T) and rs2430561 (1874 T/A), with the risk of breast cancer [25, 36, 47, 48] , but the results were in conflict with null, positive, and inverse associations, implying that the interaction between genes and infections may be important in the risk of breast cancer or other diseases. Population admixture and genetic heterogeneity would cause false associations between genetic polymorphisms and diseases. Indeed, the allelic distributions of the 2 SNPs (IL-10 rs1800871, IFN-c rs2069705) differ significantly between Chinese and whites. The frequency of the IL-10 rs1800871 C allele among the healthy controls in our study was 0.31, much lower than that in whites (0.79 in the United Kingdom) [21] . The frequency of the IFN-c rs2069705 C allele among the healthy controls was 0.73 in our study, much higher than that in whites (0.32 in the United States) [49] . However, in our study, all of the participants were Han Chinese. Hence, the results were not affected by population admixture or genetic heterogeneity. In addition, the allele frequencies obtained in our study were similar to those in other Asian populations. For example, the frequency of the IL-10 rs1800871 C allele was 0.33 in another Chinese population [29] ; the frequencies of the IFN-c rs2069705 C allele were 0.75 in a Taiwanese population and 0.81 in a Korean population [26, 50] .
To date, the interaction between EBV IgA levels and genetic markers has never to our knowledge been reported. Small sample size is a potential limitation in this type of study. However, we conducted a post hoc power calculation and found that the current sample size afforded at least 80% statistical power to detect the interaction between IFN-c rs2069705 (minor allele frequency of 0.27) and EBNA-1 IgA positivity (0.026) at a type I error of 0.05 assuming a breast cancer incidence of 40 per 100 000, although the powers were lower for other interactions and the genetic main effects. Nevertheless, further validations from larger, independent populations and prospective studies will be necessary to confirm the association and interaction between EBV IgA levels and IL-10 rs1800871 or IFN-c rs2069705 genotype on breast cancer risk. In summary, we confirmed the association of EBV IgA antibodies with the risk of breast cancer. We also found that the C allele at rs1800871 of IL-10 was associated with a decreased risk of breast cancer and there was a significant interaction between genetic polymorphism (rs2069705) in IFN-c and the seropositivity of IgA antibodies to EBV on the risk of breast cancer. These results suggest that EBV may contribute to the risk of breast cancer, and that the IgA antibodies to VCA and EBNA-1 are effective susceptible biomarkers. This contribution may be modified by genetic variations in IFN-c.
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